{"id":52154,"date":"2025-12-29T13:40:10","date_gmt":"2025-12-29T05:40:10","guid":{"rendered":"https:\/\/flcube.com\/?p=52154"},"modified":"2025-12-29T13:40:10","modified_gmt":"2025-12-29T05:40:10","slug":"kleos-health-and-bioinno-bioscience-forge-china-partnership-for-exosome-drugs-in-orthopedics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52154","title":{"rendered":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics"},"content":{"rendered":"\n<p><strong>Kleos Health Inc.<\/strong> announced the signing of a <strong>strategic cooperation agreement<\/strong> with <strong>China-based BioInno Bioscience Co., Ltd.<\/strong> to jointly develop, manufacture, and conduct clinical research on <strong>innovative extracellular exosome drugs<\/strong> for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-overview\">Partnership Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Kleos Health Inc. (U.S.), BioInno Bioscience Co., Ltd. (China)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Strategic cooperation (development, production, clinical research)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Extracellular exosome therapeutics<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Orthopedics &amp; joint diseases<\/td><\/tr><tr><td><strong>Execution Date<\/strong><\/td><td>28\u202fDec\u202f2025<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>China\u2011centric with potential Asia\u2011Pacific expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-focus-areas\">Pipeline Focus Areas<\/h2>\n\n\n\n<p>The collaboration has defined strategic priorities across six major orthopedic disease categories:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Disease Area<\/th><th>Patient Population (China)<\/th><th>Unmet Need<\/th><\/tr><\/thead><tbody><tr><td><strong>Knee osteoarthritis &amp; degenerative diseases<\/strong><\/td><td>&gt;100\u202fmillion<\/td><td>Disease\u2011modifying therapies lacking<\/td><\/tr><tr><td><strong>Shoulder arthritis &amp; injuries<\/strong><\/td><td>~30\u202fmillion<\/td><td>Limited regenerative treatment options<\/td><\/tr><tr><td><strong>Bone trauma healing &amp; repair<\/strong><\/td><td>5\u202fmillion+ fractures annually<\/td><td>Accelerated healing solutions<\/td><\/tr><tr><td><strong>Osteonecrosis of the femoral head<\/strong><\/td><td>~500,000 diagnosed<\/td><td>High unmet need beyond joint replacement<\/td><\/tr><tr><td><strong>Cervical &amp; lumbar spine diseases<\/strong><\/td><td>&gt;150\u202fmillion<\/td><td>Chronic pain management gaps<\/td><\/tr><tr><td><strong>Rheumatoid &amp; rheumatoid arthritis<\/strong><\/td><td>~6\u202fmillion<\/td><td>Biologics access &amp; affordability issues<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-amp-strategic-rationale\">Technology &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exosome Mechanism<\/strong>: Engineered extracellular vesicles delivering regenerative, anti\u2011inflammatory payloads directly to cartilage, bone, and synovial tissue<\/li>\n\n\n\n<li><strong>Advantages<\/strong>: Non\u2011invasive delivery, low immunogenicity, targeted tissue penetration, potential for off\u2011the\u2011shelf manufacturing<\/li>\n\n\n\n<li><strong>Partnership Synergy<\/strong>: Kleos contributes proprietary exosome engineering; BioInno provides China\u2011based GMP manufacturing, clinical trial infrastructure, and regulatory expertise<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: <strong>First\u2011mover position<\/strong> in exosome\u2011based orthopedics in China; no approved exosome drugs currently exist in this therapeutic area globally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-financial-implications\">Market Context &amp; Financial Implications<\/h2>\n\n\n\n<p>China\u2019s <strong>orthopedic regenerative medicine market<\/strong> is projected to reach <strong>\u00a518\u202fbillion<\/strong> (\u2248\u202fUS$2.5\u202fbillion) by 2028, growing at a 22% CAGR, driven by aging demographics and rising sports\u2011related injuries.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China osteoarthritis patients<\/strong><\/td><td>110\u202fmillion<\/td><td>120\u202fmillion<\/td><\/tr><tr><td><strong>Addressable exosome\u2011eligible cohort<\/strong><\/td><td>15\u202fmillion<\/td><td>20\u202fmillion<\/td><\/tr><tr><td><strong>Projected peak penetration<\/strong><\/td><td>2%<\/td><td>5%<\/td><\/tr><tr><td><strong>Estimated annual therapy cost<\/strong><\/td><td>\u00a525,000<\/td><td>\u00a518,000 (post\u2011volume procurement)<\/td><\/tr><tr><td><strong>Potential market size<\/strong><\/td><td>\u00a5750\u202fmillion<\/td><td>\u00a51.8\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Sharing<\/strong>: Undisclosed terms; industry norms suggest 50\/50 profit split with tiered milestone payments<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong>: First IND filing expected <strong>Q4\u202f2026<\/strong>; Phase\u202fII trials slated for <strong>2027\u20112028<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: BioInno to build dedicated exosome GMP facility in Suzhou Biotech Park (capacity: 500,000 doses\/year by 2028)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-regulatory-pathway\">Competitive Landscape &amp; Regulatory Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standard of Care<\/strong>: Symptomatic relief (NSAIDs, corticosteroids), hyaluronic acid injections, and eventual joint replacement<\/li>\n\n\n\n<li><strong>Emerging Competitors<\/strong>: <strong>CartiHeal<\/strong> (agili\u2011C) and <strong>Vericel<\/strong> (MACI) focus on cartilage implants; no direct exosome rivals in late\u2011stage development in China<\/li>\n\n\n\n<li><strong>Regulatory Advantage<\/strong>: NMPA\u2019s <strong>breakthrough therapy designation<\/strong> pathway available for regenerative medicines with strong preclinical data; potential for accelerated review<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief includes forward\u2011looking estimates regarding market size, development timelines, and partnership revenue potential. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive dynamics in the exosome therapeutics space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52158,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4520,19,4519],"class_list":["post-52154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bioinno-bioscience","tag-cro-cmo-cdmo","tag-kleos-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52154\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics\" \/>\n<meta property=\"og:description\" content=\"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52154\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-29T05:40:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics\",\"datePublished\":\"2025-12-29T05:40:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154\"},\"wordCount\":470,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2901.webp\",\"keywords\":[\"BioInno Bioscience\",\"CRO \\\/ CMO \\\/ CDMO\",\"Kleos Health\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52154#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52154\",\"name\":\"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2901.webp\",\"datePublished\":\"2025-12-29T05:40:10+00:00\",\"description\":\"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52154\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52154#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics - Insight, China&#039;s Pharmaceutical Industry","description":"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52154","og_locale":"en_US","og_type":"article","og_title":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics","og_description":"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.","og_url":"https:\/\/flcube.com\/?p=52154","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-29T05:40:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52154#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52154"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics","datePublished":"2025-12-29T05:40:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52154"},"wordCount":470,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52154#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","keywords":["BioInno Bioscience","CRO \/ CMO \/ CDMO","Kleos Health"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52154#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52154","url":"https:\/\/flcube.com\/?p=52154","name":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52154#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52154#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","datePublished":"2025-12-29T05:40:10+00:00","description":"Kleos Health Inc. announced the signing of a strategic cooperation agreement with China-based BioInno Bioscience Co., Ltd. to jointly develop, manufacture, and conduct clinical research on innovative extracellular exosome drugs for orthopedic and joint diseases, targeting a market with limited disease\u2011modifying options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52154#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52154"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52154#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","width":1080,"height":608,"caption":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52154#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52154"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52154\/revisions"}],"predecessor-version":[{"id":52159,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52154\/revisions\/52159"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52158"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}